Although medical marijuana reforms are now in thirty-three states out of fifty states, it might be wrong to think that CBD has to be legalized in the United States of America.
Despite the 2018 Farm bill that authorized industrial hemp and that cannabis continues gaining popularity across the US, government departments are still digesting CBD rules.
With the Farm Bill’s exclusion of industrial hemp from the Schedule I Controlled Substances, hemp’s jurisdiction has been moved from DEA(Drug Enforcement Administration) to the USDA( U.S Department of Agriculture). However, like other products sold in America, CBD hemp-extracts are also subject to the FDC( Food, Drug, and Cosmetics) Act, which oversees goods after examining them for safety purposes. The process is extremely slow but thorough.
The FDC Act allows the FDA to conduct clinical trials on drugs, foods, food additives, dietary supplements, tobacco products, animal foods and cosmetics. The FDA is also in charge of dosing and labelling of food supplements and drugs.
The FDA has recognized the merits of marijuana use for seizure conditions through the legalization of Epiodex, that has assisted patients suffering from Lennox-Gastaut Syndrome and Dravet Syndrome. The product entails high CBD and THC levels (100mg per ml) and was the first marijuana-derived drug to get FDA legalization.
However, more research is desperately required. As CBD garners more popularity, the market grows with potentially detrimental outcomes. CBD retailers have been warned severally by the FDA concerning deceptive health claims, adulterated products and mislabeling.
FDA understands that appropriate CBD regulations are necessary. This comprehension was recently highlighted when the department hosted a 12-hour summit that disclosed its view on CBD as well as other cannabinoids.
Although the conference focused on Women’s health, the officials at the event (FDA representatives and other multiple representatives of private research organizations and medical schools) acknowledged the rising public interest in cannabinoids.